94 related articles for article (PubMed ID: 26116990)
21. A physiologically based pharmacokinetic model of alvespimycin in mice and extrapolation to rats and humans.
Hu ZY; Lu J; Zhao Y
Br J Pharmacol; 2014 Jun; 171(11):2778-89. PubMed ID: 24471734
[TBL] [Abstract][Full Text] [Related]
22. 3-Deazaneplanocin A May Directly Target Putative Cancer Stem Cells in Biliary Tract Cancer.
Mayr C; Wagner A; Stoecklinger A; Jakab M; Illig R; Berr F; Pichler M; Di Fazio P; Ocker M; Neureiter D; Kiesslich T
Anticancer Res; 2015 Sep; 35(9):4697-705. PubMed ID: 26254359
[TBL] [Abstract][Full Text] [Related]
23. Preclinical pharmacokinetic analysis of felotaxel (SHR110008), a novel derivative of docetaxel, in rats and its protein binding ability in vitro.
Ding Y; Liu W; Lu C; Yang J; Zhu Y; Song Y; Ma Z; Yang L; Jia Y; Wen A
Biomed Pharmacother; 2012 Mar; 66(2):98-102. PubMed ID: 22264880
[TBL] [Abstract][Full Text] [Related]
24. Genome-wide analysis revealed that DZNep reduces tubulointerstitial fibrosis via down-regulation of pro-fibrotic genes.
Mimura I; Hirakawa Y; Kanki Y; Nakaki R; Suzuki Y; Tanaka T; Aburatani H; Nangaku M
Sci Rep; 2018 Feb; 8(1):3779. PubMed ID: 29491489
[TBL] [Abstract][Full Text] [Related]
25. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.
De Buck SS; Sinha VK; Fenu LA; Nijsen MJ; Mackie CE; Gilissen RA
Drug Metab Dispos; 2007 Oct; 35(10):1766-80. PubMed ID: 17620347
[TBL] [Abstract][Full Text] [Related]
26. Predictions of tissue concentrations of myclobutanil, oxyfluorfen, and pronamide in rat and human after oral exposures via GastroPlus
Zhang F; Erskine TC; McClymont EL; Moore LM; LeBaron MJ; McNett D; Marty SS
SAR QSAR Environ Res; 2024 Apr; 35(4):285-307. PubMed ID: 38588502
[TBL] [Abstract][Full Text] [Related]
27. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
[TBL] [Abstract][Full Text] [Related]
29. Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.
Choo EF; Belvin M; Boggs J; Deng Y; Hoeflich KP; Ly J; Merchant M; Orr C; Plise E; Robarge K; Martini JF; Kassees R; Aoyama RG; Ramaiya A; Johnston SH
Drug Metab Dispos; 2012 May; 40(5):919-27. PubMed ID: 22315332
[TBL] [Abstract][Full Text] [Related]
30. Pre-clinical pharmacokinetics and acute toxicological evaluation of a monastrol derivative anticancer candidate LaSOM 65 in rats.
Torres BG; Uchôa Fde T; Pigatto MC; Azeredo FJ; Haas SE; Dallegrave E; Canto RF; Eifler-Lima VL; Dalla Costa T
Xenobiotica; 2014 Mar; 44(3):254-63. PubMed ID: 23937080
[TBL] [Abstract][Full Text] [Related]
31. Physiologically based pharmacokinetic model of docetaxel and interspecies scaling: comparison of simple injection with folate receptor-targeting amphiphilic copolymer-modified liposomes.
Lu XF; Bi K; Chen X
Xenobiotica; 2016 Dec; 46(12):1093-1104. PubMed ID: 26986924
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity and pharmacokinetic properties of ARS-interacting multi-functional protein 1 (AIMP1/p43).
Han JM; Myung H; Kim S
Cancer Lett; 2010 Jan; 287(2):157-64. PubMed ID: 19573982
[TBL] [Abstract][Full Text] [Related]
33. Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice.
Zhang L; Mager DE
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):541-52. PubMed ID: 26391023
[TBL] [Abstract][Full Text] [Related]
34. Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic-pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor.
Liederer BM; Berezhkovskiy LM; Dean BJ; Dinkel V; Peng J; Merchant M; Plise EG; Wong H; Liu X
Xenobiotica; 2011 Apr; 41(4):327-39. PubMed ID: 21182395
[TBL] [Abstract][Full Text] [Related]
35. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
36. A semiphysiologically based pharmacokinetic modeling approach to predict the dose-exposure relationship of an antiparasitic prodrug/active metabolite pair.
Yan GZ; Generaux CN; Yoon M; Goldsmith RB; Tidwell RR; Hall JE; Olson CA; Clewell HJ; Brouwer KL; Paine MF
Drug Metab Dispos; 2012 Jan; 40(1):6-17. PubMed ID: 21953913
[TBL] [Abstract][Full Text] [Related]
37. S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition.
Hayden A; Johnson PW; Packham G; Crabb SJ
Breast Cancer Res Treat; 2011 May; 127(1):109-19. PubMed ID: 20556507
[TBL] [Abstract][Full Text] [Related]
38. Prediction of pharmacokinetic profile of valsartan in humans based on in vitro uptake-transport data.
Poirier A; Cascais AC; Funk C; Lavé T
Chem Biodivers; 2009 Nov; 6(11):1975-87. PubMed ID: 19937834
[TBL] [Abstract][Full Text] [Related]
39. Dznep, a histone modification inhibitor, inhibits HIF1α binding to TIMP2 gene and suppresses TIMP2 expression under hypoxia.
Yamazaki T; Mimura I; Kurata Y; Tanaka T; Nangaku M
Physiol Rep; 2023 Sep; 11(17):e15810. PubMed ID: 37710084
[TBL] [Abstract][Full Text] [Related]
40. Preclinical pharmacology of the natural product anticancer agent 10-hydroxycamptothecin, an inhibitor of topoisomerase I.
Zhang R; Li Y; Cai Q; Liu T; Sun H; Chambless B
Cancer Chemother Pharmacol; 1998; 41(4):257-67. PubMed ID: 9488594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
